Leukemia Leukemia covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction, molecular targets for therapy and more. http://feeds.nature.com/leu/rss/current Nature Publishing Group en © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Leukemia © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com Leukemia https://www.nature.com/uploads/product/leu/rss.gif http://feeds.nature.com/leu/rss/current <![CDATA[Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights]]> https://www.nature.com/articles/s41375-024-02233-7 Leukemia, Published online: 28 March 2024; doi:10.1038/s41375-024-02233-7

Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights]]>
Shyam SrinivasanSwaminathan Keerthivasagam doi:10.1038/s41375-024-02233-7 Leukemia, Published online: 2024-03-28; | doi:10.1038/s41375-024-02233-7 2024-03-28 Leukemia 10.1038/s41375-024-02233-7 https://www.nature.com/articles/s41375-024-02233-7
<![CDATA[Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry]]> https://www.nature.com/articles/s41375-024-02204-y Leukemia, Published online: 28 March 2024; doi:10.1038/s41375-024-02204-y

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry]]>
Annamaria BrioliElza LomaiaChristian FabischTomasz SachaHana KlamovaElena MorozovaAleksandra GolosPhilipp ErnstUlla Olsson-StrombergDaniela ZackovaFranck E. NicoliniHan BaoFausto CastagnettiElzbieta PatkowskaJiri MayerKlaus HirschbühlHelena PodgornikEdyta PaczkowskaAnne ParryThomas ErnstAstghik VoskanyanElzbieta SzczepanekSusanne SausseleGeorg-Nikolaus FrankeAlexander KianiEdgar FaberStefan KrauseLuis Felipe CasadoKrzysztof LewandowskiMatthias EderPeter AnhutJustyna GilThomas SüdhoffHolger HebartSonja HeiblMarkus PfirrmannAndreas HochhausMichael Lauseker doi:10.1038/s41375-024-02204-y Leukemia, Published online: 2024-03-28; | doi:10.1038/s41375-024-02204-y 2024-03-28 Leukemia 10.1038/s41375-024-02204-y https://www.nature.com/articles/s41375-024-02204-y
<![CDATA[ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?]]> https://www.nature.com/articles/s41375-024-02225-7 Leukemia, Published online: 27 March 2024; doi:10.1038/s41375-024-02225-7

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?]]>
Olaf PenackMouad AbouqatebChristophe PeczynskiWilliam BorelandNicolaus KrögerMatthias StelljesTobias Gedde-DahlIgor Wolfgang BlauThomas SchroederUrpu SalmenniemiAlexander KulaginRégis Peffault de LatourStephan MielkeRobert ZeiserIvan MoiseevHélène SchoemansChristian KoeneckeZinaida Peric doi:10.1038/s41375-024-02225-7 Leukemia, Published online: 2024-03-27; | doi:10.1038/s41375-024-02225-7 2024-03-27 Leukemia 10.1038/s41375-024-02225-7 https://www.nature.com/articles/s41375-024-02225-7
<![CDATA[Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial]]> https://www.nature.com/articles/s41375-024-02231-9 Leukemia, Published online: 27 March 2024; doi:10.1038/s41375-024-02231-9

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial]]>
Michael OertelMarita ZiepertFabian FrontzekNina NackeBettina AltmannMaike NickelsenBertram GlassViola PoeschelChristian RuebeGeorg LenzNorbert SchmitzHans Theodor Eich doi:10.1038/s41375-024-02231-9 Leukemia, Published online: 2024-03-27; | doi:10.1038/s41375-024-02231-9 2024-03-27 Leukemia 10.1038/s41375-024-02231-9 https://www.nature.com/articles/s41375-024-02231-9
<![CDATA[Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients]]> https://www.nature.com/articles/s41375-024-02230-w Leukemia, Published online: 27 March 2024; doi:10.1038/s41375-024-02230-w

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients]]>
Shai ShimonyJacqueline S. GarciaJulia KeatingEvan C. ChenMarlise R. LuskinMaximilian StahlDonna S. NeubergDaniel J. DeAngeloRichard M. StoneR. Coleman Lindsley doi:10.1038/s41375-024-02230-w Leukemia, Published online: 2024-03-27; | doi:10.1038/s41375-024-02230-w 2024-03-27 Leukemia 10.1038/s41375-024-02230-w https://www.nature.com/articles/s41375-024-02230-w
<![CDATA[Are there new relevant therapeutic endpoints in the modern era of the <i>BCR::ABL1</i> tyrosine kinase inhibitors in chronic myeloid leukemia?]]> https://www.nature.com/articles/s41375-024-02229-3 Leukemia, Published online: 26 March 2024; doi:10.1038/s41375-024-02229-3

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?]]>
BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?]]> Hagop KantarjianSusan BranfordMassimo BrecciaJorge CortesFadi G. HaddadAndreas HochhausTimothy HughesGhayas C. IssaElias JabbourFranck E. NicoliniKoji SasakiFrancois Xavier-Mahon doi:10.1038/s41375-024-02229-3 Leukemia, Published online: 2024-03-26; | doi:10.1038/s41375-024-02229-3 2024-03-26 Leukemia 10.1038/s41375-024-02229-3 https://www.nature.com/articles/s41375-024-02229-3
<![CDATA[Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy]]> https://www.nature.com/articles/s41375-024-02208-8 Leukemia, Published online: 26 March 2024; doi:10.1038/s41375-024-02208-8

Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy]]>
Eduardo Sabino de Camargo MagalhãesStefan Edward HubnerBrandon Douglas BrownYihua QiuSteven Mitchell Kornblau doi:10.1038/s41375-024-02208-8 Leukemia, Published online: 2024-03-26; | doi:10.1038/s41375-024-02208-8 2024-03-26 Leukemia 10.1038/s41375-024-02208-8 https://www.nature.com/articles/s41375-024-02208-8
<![CDATA[Measurable residual disease quantification in adult patients with <i>KMT2A</i>-rearranged acute lymphoblastic leukemia]]> https://www.nature.com/articles/s41375-024-02209-7 Leukemia, Published online: 22 March 2024; doi:10.1038/s41375-024-02209-7

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia]]>
KMT2A-rearranged acute lymphoblastic leukemia]]> Thomas BurmeisterAeint-Steffen StröhBritta KehdenHeiko TrautmannClaus MeyerRolf MarschalekPatrizia LargheroStefan SchwartzBjörn SteffenBernd SpriewaldThomas HeinickeNadja JäkelJörg WestermannKathrin NachtkampAndreas ViardotMax S. ToppMartin NeumannClaudia D. BaldusNicola GökbugetMonika Brüggemann doi:10.1038/s41375-024-02209-7 Leukemia, Published online: 2024-03-22; | doi:10.1038/s41375-024-02209-7 2024-03-22 Leukemia 10.1038/s41375-024-02209-7 https://www.nature.com/articles/s41375-024-02209-7